THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, September 18, 2020
The promotion of Dr. Linnea Schmidt to the position of CRQE will lead Frestedt in its strategic growth.
FREMONT, CA: Frestedt announces the promotion of Dr. Linnea Schmidt to the position of CRQE II. In this position, Dr. Schmidt will be taking on added responsibility for many of the clinical, regulatory, quality, and engineering projects at Frestedt. Dr. Schmidt finds many FDA slide decks emphasize past safety problems with drugs and devices intended for women and expresses a desire to work on more women’s health issues, particularly related to issues of safety and appropriate labeling for drugs, devices, and foods used by women. In the past two years, Dr. Schmidt has updated several drug labels to be compliant with the final regulatory rule entitled Content and Format of Labeling for Human Prescription Drug and Biological Products: Requirements for Pregnancy and Lactation Labeling, which is also known simply as the “Pregnancy and Lactation Labeling Rule” (PLLR), published in December 2014.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Dr. Linnea Schmidt is a biomedical scientist passionate about scientific communication. She has deep expertise in clinical, regulatory, and quality affairs experience for pre- and post-market drugs and medical devices. Linnea will be responsible for ensuring the quality by following and writing internal and external SOPs, work instructions, and forms/templates to successfully prepare robust, high-quality deliverables. She will also be in charge of project management, including planning, implementation, prioritization, and data analysis on behalf of clients to keep projects on time, high quality, and within budgets.
Frestedt is a consulting service organization providing targeted clinical, regulatory, and quality system solutions for the pharmaceutical, medical device, biotechnology, and food-related industries. The company also offers design and development leadership to research centers running clinical trials and regulatory submissions to improve the quality and cost-effectiveness of the research service. “What truly differentiates us in the marketplace is our approach to tailor each client endeavor to facilitate a timely and high-quality outcome always in compliance with the regulatory requirements,” asserts Dr. Joy Frestedt, President and CEO at Frestedt.
Frestedt was featured in Pharma Tech Outlook as one of the Top 10 CROs 2019.
More in News